[{"orgOrder":0,"company":"NattoPharma","sponsor":"Gnosis by Lesaffre","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Vitamin K2","moa":"SXR","graph1":"Musculoskeletal","graph2":"Approved","graph3":"NattoPharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"NattoPharma \/ Gnosis","highestDevelopmentStatusID":"12","companyTruncated":"NattoPharma \/ Gnosis"}]

Find Clinical Drug Pipeline Developments & Deals by NattoPharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : This acquisition brings together globally recognized vitamin K2 brands vitaMK7® and MenaQ7® and allows Gnosis by Lesaffre to offer to the market the most complete portfolio of solutions, adapted to each market need and able to satisfy all customers.

                          Brand Name : MenaQ7

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 25, 2021

                          Lead Product(s) : Vitamin K2

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved

                          Sponsor : Gnosis by Lesaffre

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank